USE OF ANTAGONISTS OF TH17 CYTOKINES FOR THE TREATMENT OF BRONCHIAL REMODELING IN PATIENTS SUFFERING FROM ALLERGIC ASTHMA
Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines...
Gespeichert in:
Hauptverfasser: | , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | TSICOPOULOS, Anne BOUTE, Mélodie VORNG, Han CHENIVESSE, Cécile NANOU, Julie AIT YAHIA SENDED, Saliha |
description | Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2022033486A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2022033486A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2022033486A13</originalsourceid><addsrcrecordid>eNqNyrsKwkAQheE0FqK-w4C1kIuo7bjOZhf3IruTwioEWSvRQGx8exPwAawO5-ebZ58mEngJ6Bhr73TkOF1WxR7Elf1ZO4ogfRgTAQdCtuR4MsfgnVAaDQSy_kRGuxq0gwuyHkmE2EhJYaoyeAtoDIVaC8DIyuIym927x5BWv11ka0ks1Cb1rzYNfXdLz_Rum1jmZZlX1faww6L6T30BkNk69Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>USE OF ANTAGONISTS OF TH17 CYTOKINES FOR THE TREATMENT OF BRONCHIAL REMODELING IN PATIENTS SUFFERING FROM ALLERGIC ASTHMA</title><source>esp@cenet</source><creator>TSICOPOULOS, Anne ; BOUTE, Mélodie ; VORNG, Han ; CHENIVESSE, Cécile ; NANOU, Julie ; AIT YAHIA SENDED, Saliha</creator><creatorcontrib>TSICOPOULOS, Anne ; BOUTE, Mélodie ; VORNG, Han ; CHENIVESSE, Cécile ; NANOU, Julie ; AIT YAHIA SENDED, Saliha</creatorcontrib><description>Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220203&DB=EPODOC&CC=US&NR=2022033486A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220203&DB=EPODOC&CC=US&NR=2022033486A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TSICOPOULOS, Anne</creatorcontrib><creatorcontrib>BOUTE, Mélodie</creatorcontrib><creatorcontrib>VORNG, Han</creatorcontrib><creatorcontrib>CHENIVESSE, Cécile</creatorcontrib><creatorcontrib>NANOU, Julie</creatorcontrib><creatorcontrib>AIT YAHIA SENDED, Saliha</creatorcontrib><title>USE OF ANTAGONISTS OF TH17 CYTOKINES FOR THE TREATMENT OF BRONCHIAL REMODELING IN PATIENTS SUFFERING FROM ALLERGIC ASTHMA</title><description>Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyrsKwkAQheE0FqK-w4C1kIuo7bjOZhf3IruTwioEWSvRQGx8exPwAawO5-ebZ58mEngJ6Bhr73TkOF1WxR7Elf1ZO4ogfRgTAQdCtuR4MsfgnVAaDQSy_kRGuxq0gwuyHkmE2EhJYaoyeAtoDIVaC8DIyuIym927x5BWv11ka0ks1Cb1rzYNfXdLz_Rum1jmZZlX1faww6L6T30BkNk69Q</recordid><startdate>20220203</startdate><enddate>20220203</enddate><creator>TSICOPOULOS, Anne</creator><creator>BOUTE, Mélodie</creator><creator>VORNG, Han</creator><creator>CHENIVESSE, Cécile</creator><creator>NANOU, Julie</creator><creator>AIT YAHIA SENDED, Saliha</creator><scope>EVB</scope></search><sort><creationdate>20220203</creationdate><title>USE OF ANTAGONISTS OF TH17 CYTOKINES FOR THE TREATMENT OF BRONCHIAL REMODELING IN PATIENTS SUFFERING FROM ALLERGIC ASTHMA</title><author>TSICOPOULOS, Anne ; BOUTE, Mélodie ; VORNG, Han ; CHENIVESSE, Cécile ; NANOU, Julie ; AIT YAHIA SENDED, Saliha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2022033486A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>TSICOPOULOS, Anne</creatorcontrib><creatorcontrib>BOUTE, Mélodie</creatorcontrib><creatorcontrib>VORNG, Han</creatorcontrib><creatorcontrib>CHENIVESSE, Cécile</creatorcontrib><creatorcontrib>NANOU, Julie</creatorcontrib><creatorcontrib>AIT YAHIA SENDED, Saliha</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TSICOPOULOS, Anne</au><au>BOUTE, Mélodie</au><au>VORNG, Han</au><au>CHENIVESSE, Cécile</au><au>NANOU, Julie</au><au>AIT YAHIA SENDED, Saliha</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>USE OF ANTAGONISTS OF TH17 CYTOKINES FOR THE TREATMENT OF BRONCHIAL REMODELING IN PATIENTS SUFFERING FROM ALLERGIC ASTHMA</title><date>2022-02-03</date><risdate>2022</risdate><abstract>Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_epo_espacenet_US2022033486A1 |
source | esp@cenet |
subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | USE OF ANTAGONISTS OF TH17 CYTOKINES FOR THE TREATMENT OF BRONCHIAL REMODELING IN PATIENTS SUFFERING FROM ALLERGIC ASTHMA |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A43%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TSICOPOULOS,%20Anne&rft.date=2022-02-03&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2022033486A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |